Tuning the Rigging before Sailing off into the Stormy Sea of Stem Cell Transplants for Patients with Myelodysplastic Syndromes

Biology of Blood and Marrow Transplantation

Volumn 18, Issue 8, 2012, Pages 1145-1147

  Steensma, David P ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; BONE MARROW TRANSPLANTATION; CHEMOTHERAPY; CLINICAL PRACTICE; CYTOPENIA; GRAFT VERSUS LEUKEMIA EFFECT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MEDICAL RESEARCH; MINIMAL RESIDUAL DISEASE; MORTALITY; MYELODYSPLASTIC SYNDROME; NOTE; PROGNOSIS; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME; UNITED STATES;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AZACITIDINE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MYELODYSPLASTIC SYNDROMES;

EID: 84864003788     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2012.05.004     Document Type: Note

References (22)

1. Sekeres M.A. Are we nearer to curing patients with MDS?. Best Pract Res Clin Haematol 2010, 23:481-487.
2. Sekeres M.A., Schoonen W.M., Kantarjian H., et al. Characteristics of US patients with myelodysplastic syndromes: results of six cross-sectional physician surveys. J Natl Cancer Inst 2008, 100:1542-1551.
3. Cogle C.R., Craig B.M., Rollison D.E., List A.F. Incidence of the myelodysplastic syndromes using a novel claims-based algorithm: high number of uncaptured cases by cancer registries. Blood 2011, 117:7121-7125.
4. Pasquini M, Wang Z. Current use and outcome of hematopoietic stem cell transplantation: CIBMTR Summary Slides, 2011. (See slide #8). Available at: 2011. Accessed June 6, 2012. http://www.cibmtr.org.
5. Parmar S., de Lima M., Deeg H.J., Champlin R. Hematopoietic stem cell transplantation for myelodysplastic syndrome: a review. Semin Oncol 2011, 38:693-704.
6. Martino R., Caballero M.D., Pérez-Simón J.A., et al. Evidence for a graft-versus-leukemia effect after allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning in acute myelogenous leukemia and myelodysplastic syndromes. Blood 2002, 100:2243-2245.
7. Luger S.M., Ringdén O., Zhang M.J., et al. Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDS. Bone Marrow Transplant 2012, 47:203-211.
8. van Besien K., Artz A., Smith S., et al. Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol 2005, 23:5728-5738.
9. Kebriaei P., Kline J., Stock W., et al. Impact of disease burden at time of allogeneic stem cell transplantation in adults with acute myeloid leukemia and myelodysplastic syndromes. Bone Marrow Transplant 2005, 35:965-970.
10. Walter M.J., Shen D., Ding L., et al. Clonal architecture of secondary acute myeloid leukemia. N Engl J Med 2012, 366:1090-1098.
11. Lim Z., Brand R., Martino R., et al. Allogeneic hematopoietic stem-cell transplantation for patients 50 years or older with myelodysplastic syndromes or secondary acute myeloid leukemia. J Clin Oncol 2010, 28:405-411.
12. Estey E., de Lima M., Tibes R., et al. Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). Blood 2007, 109:1395-1400.
13. Kim D.Y., Lee J.H., Park Y.H., et al. Feasibility of hypomethylating agents followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome. Bone Marrow Transplant 2012, 47:374-379.
14. Field T., Perkins J., Huang Y., et al. 5-Azacitidine for myelodysplasia before allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 2010, 45:255-260.
15. Cogle C.R., Imanirad I., Wiggins L.E., et al. Hypomethylating agent induction therapy followed by hematopoietic cell transplantation is feasible in patients with myelodysplastic syndromes. Clin Adv Hematol Oncol 2010, 8:40-46.
16. De Padua Silva L., de Lima M., Kantarjian H., et al. Feasibility of allo-SCT after hypomethylating therapy with decitabine for myelodysplastic syndrome. Bone Marrow Transplant 2009, 43:839-843.
17. Lübbert M., Bertz H., Rüter B., et al. Non-intensive treatment with low-dose 5-aza-2'-deoxycytidine (DAC) prior to allogeneic blood SCT of older MDS/AML patients. Bone Marrow Transplant 2009, 44:585-588.
18. Bejar R., Stevenson K., Abdel-Wahab O., et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med 2011, 364:2496-2506.
19. Gerds A.T., Gooley T.A., Estey E.H., Appelbaum F.R., Deeg H.J., Scott B.L. Pretransplantation therapy with azacitidine vs induction chemotherapy and posttransplantation outcome in patients with MDS. Biol Blood Marrow Transplant 2012, 18:1211-1218.
20. Issa J.P. Epigenetic changes in the myelodysplastic syndrome. Hematol Oncol Clin North Am 2010, 24:317-330.
21. Goodyear O.C., Dennis M., Jilani N.Y., et al. Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML). Blood 2012, 119:3361-3369.
22. de Lima M., Giralt S., Thall P.F., et al. Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study. Cancer 2010, 116:5420-5431.